Study to Evaluate the Pharmacokinetics of Firsocostat or Fenofibrate in Adults With Normal and Impaired Hepatic Function
Completed · Phase 1
Conditions studied: Nonalcoholic Steatohepatitis (NASH)
In brief
The primary objectives of this study are to evaluate the single-dose pharmacokinetics (PK) of firsocostat in adults with normal hepatic function, and mild, moderate, or severe hepatic impairment and to evaluate the single-dose PK of fenofibrate in adults with normal hepatic function and mild hepatic impairment.
Key facts
- Study ID
- NCT02891408
- Run by
- Gilead Sciences
- People needed
- 74
- Starts
- 2016-09-23
- Expected to finish
- 2019-05-13
- Last updated by the study team
- 2020-12-17
Who can join
Age: 18 and older, up to 70. Sex: any. Healthy volunteers: accepted.
Where it is running
- Study site — Tustin, California, United States
- Study site — Miami, Florida, United States
- Study site — Orlando, Florida, United States
- Study site — Minneapolis, Minnesota, United States
- Study site — San Antonio, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.